Ziftomenib治疗复发或难治性NPM1突变型急性髓系白血病
KOMET-001 II期注册研究纳入92例复发/难治性NPM1突变型AML患者,接受ziftomenib 600 mg每日一次口服。主要终点CR/CRh率为22%(95%CI 14-32,P=.0058),总缓解率33%,中位缓解持续时间4.6个月,中位总生存期6.6个月。常见≥3级治疗相关不良事件为发热性中性粒细胞减少(26%)、贫血(20%)和血小板减少(20%),分化综合征发生率25%。
要点
- ziftomenib 600 mg每日一次在复发/难治性NPM1突变型AML中CR/CRh率达22%。
- 分化综合征发生率25%(15%为3级,无4-5级),经方案定义措施可管理。
- 3%患者因ziftomenib相关不良事件终止治疗。
核心结论
- Ziftomenib在经重度治疗的复发/难治性NPM1突变型AML患者中显示出显著临床获益和深度缓解。
- Ziftomenib耐受性良好,安全性特征与既往研究一致,包括可管理的分化综合征、无临床显著QTc延长和低骨髓抑制率。
研究设计与样本
- KOMET-001为I期试验,其II期注册部分纳入复发/难治性NPM1突变型AML患者。
- 患者接受ziftomenib 600 mg每日一次口服。
- 主要终点为完全缓解伴全部血液学恢复(CR)/伴部分血液学恢复的完全缓解(CRh)率。
主要发现
- 2023年1月26日至2024年5月13日,共92例患者接受治疗,中位年龄69岁(范围33-84岁)。
- 主要终点达到,CR/CRh率为22%(95%CI 14-32,P=.0058);其中61%为可测量残留病灶阴性。
- 总缓解率为33%(95%CI 23-43),中位缓解持续时间为4.6个月(95%CI 2.8-7.4)。
- 预设亚组分析显示,无论既往治疗(包括venetoclax)或共突变类型如何,CR/CRh率相当。
- 中位总生存期为6.6个月(95%CI 3.6-8.6)。
关键数值与推荐
- 常见≥3级治疗中出现的不良事件为发热性中性粒细胞减少(26%)、贫血(20%)和血小板减少(20%)。
- 分化综合征发生于25%的患者(15%为3级;无4-5级),经方案定义的缓解措施可管理。
- 3例患者(3%)因ziftomenib相关不良事件终止治疗。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Ziftomenib-a potent, highly selective, oral menin inhibitor-was well tolerated and demonstrated encouraging clinical activity as monotherapy for relapsed/refractory NPM1-mutated (NPM1-m) and KMT2A-rearranged AML in the KOMET-001 phase I trial. METHODS: In the registration-enabling phase II part of KOMET-001, patients with relapsed/refractory NPM1-m AML received ziftomenib 600 mg once daily. The primary end point was the rate of complete remission with full hematologic recovery (CR)/CR with partial hematologic recovery (CRh). RESULTS: From January 26, 2023, to May 13, 2024, 92 patients (median age, 69 years [range, 33-84]) were treated. The primary end point was met, with a CR/CRh rate of 22% (95% CI, 14 to 32; P = .0058); 61% were negative for measurable residual disease. Overall response rate was 33% (95% CI, 23 to 43), with a median duration of 4.6 months (95% CI, 2.8 to 7.4). Prespecified subgroup analyses showed comparable CR/CRh regardless of previous therapy, including venetoclax, or type of comutations. Median overall survival was 6.6 months (95% CI, 3.6 to 8.6). Common grade ≥3 treatment-emergent adverse events were febrile neutropenia (26%), anemia (20%), and thrombocytopenia (20%). Differentiation syndrome occurred in 25% of patients (15% grade 3; no grade 4-5) and was manageable with protocol-defined mitigation. Three patients (3%) discontinued treatment because of ziftomenib-related adverse events. CONCLUSION: Ziftomenib demonstrated significant clinical benefit and deep responses in patients with heavily pretreated, relapsed/refractory NPM1-m AML. Ziftomenib was well tolerated with a safety profile consistent with previous studies, including manageable differentiation syndrome, lack of clinically significant QTc prolongation, and low rates of myelosuppression.
引用
- Wang ES, Montesinos P, Foran J, et al. Ziftomenib in Relapsed or Refractory NPM1-Mutated AML. J Clin Oncol. 2025. PMID: 40997296. doi:10.1200/JCO-25-01694
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。